India’s First Intranasal COVID Vaccine by Bharat Biotech gets DCGI Approval 

India’s First Intranasal COVID Vaccine by Bharat Biotech gets DCGI Approval : India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19.

September 2022 Current Affairs Quiz

The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19. Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency.